{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T12:37:21Z","timestamp":1792931841108,"version":"4.5.0"},"reference-count":150,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T00:00:00Z","timestamp":1765324800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>The assessment of measurable residual disease (MRD) plays a critical role in acute myeloid leukemia (AML) treatment response evaluation and prognosis. However, current AML MRD detection by flow cytometry (FC) is limited in sensitivity due to immunophenotypic variability, similarities to normal hematopoietic stem\/progenitor cells, and the lack of stable leukemia-associated immunophenotypes. A significant proportion of AML patients classified as MRD-negative by FC eventually relapse, likely due to the persistence of therapy-resistant leukemic stem cells (LSCs) that are not sensitively detected by routine clinical flow panels. Flow cytometry panels designed to detect LSC antigens, while promising, face challenges like immunophenotypic heterogeneity across AML subtypes, lack of standardized marker panels across laboratories, and limited validation. Here, we summarize the current state of FC-based LSC detection in AML, discussing commonly used markers, immunophenotypic variability, assay setup challenges, and we review recent clinical studies on LSC assessment, outlining their main findings and implications for prognosis and MRD integration. We also consider advances in spectral flow cytometry for improved LSC detection.<\/jats:p>","DOI":"10.3389\/fphar.2025.1724473","type":"journal-article","created":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T06:35:30Z","timestamp":1765348530000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":7,"title":["Flow cytometric detection of leukemic stem cells in Acute Myeloid Leukemia: current status and future directions"],"prefix":"10.3389","volume":"16","author":[{"given":"Mariam M.","family":"Youssef","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher Y.","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,12,10]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"9104","DOI":"10.1038\/s41598-024-58689-1","article-title":"SMS121, a new inhibitor of CD36, impairs fatty acid uptake and viability of acute myeloid leukemia","volume":"14","author":"Abacka","year":"2024","journal-title":"Sci. Rep."},{"key":"B2","doi-asserted-by":"crossref","DOI":"10.1007\/978-4-431-55651-0_25","article-title":"TIM-3 is a novel therapeutic target for eradicating acute myelogenous leukemia stem cells","author":"Akashi","year":"2015"},{"key":"B3","doi-asserted-by":"publisher","first-page":"3977","DOI":"10.1158\/1078-0432.CCR-14-3186","article-title":"A leukemia-associated CD34\/CD123\/CD25\/CD99+ immunophenotype identifies FLT3-Mutated clones in acute myeloid leukemia","volume":"21","author":"Angelini","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1080\/10428194.2023.2207698","article-title":"CD69 marks a subpopulation of acute myeloid leukemia with enhanced colony forming capacity and a unique signaling activation state","volume":"64","author":"Antony","year":"2023","journal-title":"Leuk. Lymphoma"},{"key":"B5","doi-asserted-by":"publisher","first-page":"3709","DOI":"10.1182\/blood-2012-09-458935","article-title":"Selective killing of candidate AML stem cells by antibody targeting of IL1RAP","volume":"121","author":"Askmyr","year":"2013","journal-title":"Blood"},{"key":"B6","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1016\/j.ccell.2016.10.003","article-title":"CD98-Mediated adhesive signaling enables the establishment and propagation of acute myelogenous leukemia","volume":"30","author":"Bajaj","year":"2016","journal-title":"Cancer Cell"},{"key":"B7","doi-asserted-by":"publisher","first-page":"2804","DOI":"10.1073\/pnas.89.7.2804","article-title":"Isolation of a candidate human hematopoietic stem-cell population","volume":"89","author":"Baum","year":"1992","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B8","doi-asserted-by":"publisher","first-page":"2791","DOI":"10.1182\/blood-2021-152394","article-title":"Combining the expression of CD33.CAR and CXCR4 to increase CAR-CIK cell homing to bone marrow niche and leukemic stem cell eradication in acute myeloid leukemia","volume":"138","author":"Biondi","year":"2021","journal-title":"Blood"},{"key":"B9","doi-asserted-by":"publisher","first-page":"2810","DOI":"10.3324\/haematol.2022.282034","article-title":"The present and future of measurable residual disease testing in acute myeloid leukemia","volume":"107","author":"Blachly","year":"2022","journal-title":"Haematologica"},{"key":"B10","doi-asserted-by":"publisher","first-page":"2201","DOI":"10.1080\/10428194.2017.1422862","article-title":"The molecular signature of AML with increased ALDH activity suggests a stem cell origin","volume":"59","author":"Blume","year":"2018","journal-title":"Leuk. Lymphoma"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.4049\/jimmunol.1801037","article-title":"Flow cytometry: to dump or not to dump","volume":"201","author":"Boesch","year":"2018","journal-title":"J. Immunol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"612801","DOI":"10.3389\/fmolb.2020.612801","article-title":"Full spectrum flow cytometry as a powerful technology for cancer immunotherapy research","volume":"7","author":"Bonilla","year":"2020","journal-title":"Front. Mol. Biosci."},{"key":"B13","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1038\/nm0797-730","article-title":"Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell","volume":"3","author":"Bonnet","year":"1997","journal-title":"Nat. Med."},{"key":"B14","doi-asserted-by":"publisher","first-page":"56976","DOI":"10.3791\/56976","article-title":"Flow cytometry to estimate leukemia stem cells in primary acute myeloid leukemia and in patient-derived-xenografts, at diagnosis and follow up","author":"Boyer","year":"2018","journal-title":"J. Vis. Exp."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1038\/sj.leu.2401543","article-title":"Detection of cytogenetic aberrations both in CD90 (Thy-1)-positive and (Thy-1)-negative stem cell (CD34) subfractions of patients with acute and chronic myeloid leukemias","volume":"13","author":"Brendel","year":"1999","journal-title":"Leukemia"},{"key":"B16","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1111\/j.1365-2141.2004.04883.x","article-title":"CD90\/Thy\u20101 is preferentially expressed on blast cells of high risk acute myeloid leukaemias","volume":"125","author":"Buccisano","year":"2004","journal-title":"Br. Journal Haematology"},{"key":"B17","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1111\/bjh.12109","article-title":"Expression of CD25 independently predicts early treatment failure of acute myeloid leukaemia (AML)","volume":"160","author":"Cerny","year":"2013","journal-title":"Br. J. Haematol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1182\/blood.v99.1.290","article-title":"Effects of anti-CD44 monoclonal antibodies on differentiation and apoptosis of human myeloid leukemia cell lines","volume":"99","author":"Charrad","year":"2002","journal-title":"Blood"},{"key":"B19","doi-asserted-by":"publisher","first-page":"891","DOI":"10.3892\/ol.2015.3972","article-title":"Re-evaluation of various molecular targets located on CD34(+)CD38(-)Lin(-) leukemia stem cells and other cell subsets in pediatric acute myeloid leukemia","volume":"11","author":"Cheng","year":"2016","journal-title":"Oncol. Lett."},{"key":"B22","doi-asserted-by":"publisher","first-page":"eaaj2025","DOI":"10.1126\/scitranslmed.aaj2025","article-title":"CD99 is a therapeutic target on disease stem cells in myeloid malignancies","volume":"9","author":"Chung","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"B23","doi-asserted-by":"publisher","first-page":"e56386","DOI":"10.3791\/56386","article-title":"Comprehensive protocol to sample and process bone marrow for measuring measurable residual disease and leukemic stem cells in acute myeloid leukemia","author":"Cloos","year":"2018","journal-title":"J. Vis. Exp."},{"key":"B24","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1038\/leu.2011.1","article-title":"CD200 expression suppresses natural killer cell function and directly inhibits patient anti-tumor response in acute myeloid leukemia","volume":"25","author":"Coles","year":"2011","journal-title":"Leukemia"},{"key":"B25","doi-asserted-by":"publisher","first-page":"2148","DOI":"10.1038\/leu.2012.77","article-title":"Expression of CD200 on AML blasts directly suppresses memory T-cell function","volume":"26","author":"Coles","year":"2012","journal-title":"Leukemia"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1734","DOI":"10.1038\/leu.2016.76","article-title":"GPR56 contributes to the development of acute myeloid leukemia in mice","volume":"30","author":"Daria","year":"2016","journal-title":"Leukemia"},{"key":"B27","doi-asserted-by":"publisher","first-page":"57811","DOI":"10.18632\/oncotarget.11063","article-title":"Acute myeloid leukemia stem cell markers in prognosis and targeted therapy: potential impact of BMI-1, TIM-3 and CLL-1","volume":"7","author":"Darwish","year":"2016","journal-title":"Oncotarget"},{"key":"B28","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1111\/ijlh.14250","article-title":"Immunophenotypic characterization of leukemic stem cells in acute myeloid leukemia using single tube 10-colour panel by multiparametric flow cytometry: deciphering the spectrum, complexity and immunophenotypic heterogeneity","volume":"46","author":"Das","year":"2024","journal-title":"Int. J. Lab. Hematol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1056\/NEJMra1406184","article-title":"Acute myeloid leukemia","volume":"373","author":"Dohner","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"Dohner","year":"2022","journal-title":"Blood"},{"key":"B31","doi-asserted-by":"publisher","first-page":"833","DOI":"10.3892\/mco.2015.552","article-title":"Cluster of differentiation 96 as a leukemia stem cell-specific marker and a factor for prognosis evaluation in leukemia","volume":"3","author":"Du","year":"2015","journal-title":"Mol. Clin. Oncol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1038\/nm.2415","article-title":"Stem cell gene expression programs influence clinical outcome in human leukemia","volume":"17","author":"Eppert","year":"2011","journal-title":"Nat. Med."},{"key":"B33","doi-asserted-by":"publisher","first-page":"2824","DOI":"10.1158\/0008-5472.CAN-22-3682","article-title":"CD36 drives metastasis and relapse in acute myeloid leukemia","volume":"83","author":"Farge","year":"2023","journal-title":"Cancer Res."},{"key":"B34","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1002\/cyto.a.24016","article-title":"High-dimensional data analysis algorithms yield comparable results for mass cytometry and spectral flow cytometry data","volume":"97","author":"Ferrer-Font","year":"2020","journal-title":"Cytom. A"},{"key":"B35","doi-asserted-by":"publisher","first-page":"3882","DOI":"10.1182\/blood.v97.12.3882","article-title":"Hoechst 33342 efflux identifies a subpopulation of cytogenetically normal CD34(+)CD38(-) progenitor cells from patients with acute myeloid leukemia","volume":"97","author":"Feuring-Buske","year":"2001","journal-title":"Blood"},{"key":"B36","doi-asserted-by":"publisher","first-page":"2094","DOI":"10.1038\/leu.2017.29","article-title":"Next generation flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma","volume":"31","author":"Flores-Montero","year":"2017","journal-title":"Leukemia"},{"key":"B37","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.1200\/JCO.2017.76.3425","article-title":"Measurable residual disease at induction redefines partial response in acute myeloid leukemia and stratifies outcomes in patients at standard risk without NPM1 mutations","volume":"36","author":"Freeman","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.ccr.2010.12.012","article-title":"Coexistence of LMPP-Like and GMP-Like leukemia stem cells in acute myeloid leukemia","volume":"19","author":"Goardon","year":"2011","journal-title":"Cancer Cell"},{"key":"B39","doi-asserted-by":"publisher","first-page":"756231","DOI":"10.3389\/fimmu.2021.756231","article-title":"Adhesion molecules involved in stem cell niche retention during normal haematopoiesis and in acute myeloid leukaemia","volume":"12","author":"Grenier","year":"2021","journal-title":"Front. Immunol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"1079076","DOI":"10.3389\/fcell.2022.1079076","article-title":"Role of CD36 in cancer progression, stemness, and targeting","volume":"10","author":"Guerrero-Rodriguez","year":"2022","journal-title":"Front. Cell Dev. Biol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"2102","DOI":"10.3324\/haematol.2019.231944","article-title":"CD44 engagement enhances acute myeloid leukemia cell adhesion to the bone marrow microenvironment by increasing VLA-4 avidity","volume":"106","author":"Gutjahr","year":"2021","journal-title":"Haematologica"},{"key":"B42","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1111\/bjh.12277","article-title":"Flow cytometry thresholds of myeloperoxidase detection to discriminate between acute lymphoblastic or myeloblastic leukaemia","volume":"161","author":"Guy","year":"2013","journal-title":"Br. J. Haematol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1111\/bjh.14991","article-title":"Leukaemic stem cell load at diagnosis predicts the development of relapse in young acute myeloid leukaemia patients","volume":"183","author":"Hanekamp","year":"2018","journal-title":"Br. J. Haematol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.pathol.2019.09.021","article-title":"Re: myeloblasts in normal bone marrows expressing leukaemia-associated immunophenotypes","volume":"52","author":"Hanekamp","year":"2020","journal-title":"Pathology"},{"key":"B45","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1038\/s41375-018-0180-3","article-title":"Coexpression profile of leukemic stem cell markers for combinatorial targeted therapy in AML","volume":"33","author":"Haubner","year":"2019","journal-title":"Leukemia"},{"key":"B46","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1002\/ijc.29415","article-title":"Antitumor activity of an anti-CD98 antibody","volume":"137","author":"Hayes","year":"2015","journal-title":"Int. J. Cancer"},{"key":"B47","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1186\/s12885-020-06760-1","article-title":"CD45(dim)CD34(+)CD38(-)CD133(+) cells have the potential as leukemic stem cells in acute myeloid leukemia","volume":"20","author":"Heo","year":"2020","journal-title":"BMC Cancer"},{"key":"B48","doi-asserted-by":"publisher","first-page":"5118","DOI":"10.1182\/bloodadvances.2020001742","article-title":"Delineation of target expression profiles in CD34+\/CD38-and CD34+\/CD38+ stem and progenitor cells in AML and CML","volume":"4","author":"Herrmann","year":"2020","journal-title":"Blood Adv."},{"key":"B49","doi-asserted-by":"publisher","first-page":"2753","DOI":"10.1182\/blood.2021013626","article-title":"2021 update on MRD in acute myeloid leukemia: a consensus document from the european LeukemiaNet MRD working party","volume":"138","author":"Heuser","year":"2021","journal-title":"Blood, J. Am. Soc. Hematol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"2652","DOI":"10.1182\/BLOOD.V130.SUPPL_1.2652.2652","article-title":"Blocking CD70\/CD27 signaling in combination with hypomethylating agents eradicates human CD34 AML stem and progenitor cells in vitro and in vivo","volume":"130","author":"Hinterbrandner","year":"2017","journal-title":"Blood"},{"key":"B51","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1182\/blood-2016-02-695312","article-title":"Evolution of acute myelogenous leukemia stem cell properties after treatment and progression","volume":"128","author":"Ho","year":"2016","journal-title":"Blood"},{"key":"B52","doi-asserted-by":"publisher","first-page":"5402","DOI":"10.1182\/bloodadvances.2020001802","article-title":"CD200 expression marks leukemia stem cells in human AML","volume":"4","author":"Ho","year":"2020","journal-title":"Blood Adv."},{"key":"B53","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1002\/ijc.29410","article-title":"The rarity of ALDH(+) cells is the key to separation of normal versus leukemia stem cells by ALDH activity in AML patients","volume":"137","author":"Hoang","year":"2015","journal-title":"Int. J. Cancer"},{"key":"B54","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1182\/blood.v86.1.60.bloodjournal86160","article-title":"Characterization of Thy-1 (CDw90) expression in CD34+ acute leukemia","volume":"86","author":"Holden","year":"1995","journal-title":"Blood"},{"key":"B55","doi-asserted-by":"publisher","first-page":"11008","DOI":"10.1073\/pnas.0704271104","article-title":"CD96 is a leukemic stem cell-specific marker in human acute myeloid leukemia","volume":"104","author":"Hosen","year":"2007","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B56","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1007\/s00277-012-1501-7","article-title":"Flow cytometric quantification and immunophenotyping of leukemic stem cells in acute myeloid leukemia","volume":"91","author":"Hwang","year":"2012","journal-title":"Ann. Hematol."},{"key":"B57","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/s0925-5710(97)00051-0","article-title":"Flow cytometric analysis of Thy-1 expression in CD34-positive acute leukemia","volume":"66","author":"Inaba","year":"1997","journal-title":"Int. J. Hematol."},{"key":"B58","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1056\/NEJMoa1507471","article-title":"Assessment of minimal residual disease in standard-risk AML","volume":"374","author":"Ivey","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"B59","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1016\/j.stem.2015.08.008","article-title":"CD93 marks a non-quiescent human leukemia stem cell population and is required for development of MLL-rearranged acute myeloid leukemia","volume":"17","author":"Iwasaki","year":"2015","journal-title":"Cell Stem Cell"},{"key":"B60","doi-asserted-by":"publisher","first-page":"5009","DOI":"10.1073\/pnas.1100551108","article-title":"Prospective separation of normal and leukemic stem cells based on differential expression of TIM3, a human acute myeloid leukemia stem cell marker","volume":"108","author":"Jan","year":"2011","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B61","doi-asserted-by":"publisher","first-page":"149ra118","DOI":"10.1126\/scitranslmed.3004315","article-title":"Clonal evolution of preleukemic hematopoietic stem cells precedes human acute myeloid leukemia","volume":"4","author":"Jan","year":"2012","journal-title":"Sci. Transl. Med."},{"key":"B62","doi-asserted-by":"publisher","first-page":"113361","DOI":"10.1016\/j.yexcr.2022.113361","article-title":"CD93 promotes acute myeloid leukemia development and is a potential therapeutic target","volume":"420","author":"Jia","year":"2022","journal-title":"Exp. Cell Res."},{"key":"B63","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1038\/nm1483","article-title":"Targeting of CD44 eradicates human acute myeloid leukemic stem cells","volume":"12","author":"Jin","year":"2006","journal-title":"Nat. Med."},{"key":"B64","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.stem.2009.04.018","article-title":"Monoclonal antibody-mediated targeting of CD123, IL-3 receptor alpha chain, eliminates human acute myeloid leukemic stem cells","volume":"5","author":"Jin","year":"2009","journal-title":"Cell Stem Cell"},{"key":"B65","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.1038\/sj.leu.2401903","article-title":"The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells","volume":"14","author":"Jordan","year":"2000","journal-title":"Leukemia"},{"key":"B66","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1007\/978-981-13-7342-8_5","article-title":"Leukemia stem cells in the pathogenesis, progression, and treatment of acute myeloid leukemia","volume":"1143","author":"Joshi","year":"2019","journal-title":"Adv. Exp. Med. Biol."},{"key":"B67","doi-asserted-by":"publisher","first-page":"730899","DOI":"10.3389\/fonc.2021.730899","article-title":"Stem cells in myelodysplastic syndromes and acute myeloid leukemia: first cousins or unrelated entities?","volume":"11","author":"Joudinaud","year":"2021","journal-title":"Front. Oncol."},{"key":"B68","doi-asserted-by":"publisher","first-page":"e0209295","DOI":"10.1371\/journal.pone.0209295","article-title":"Expression of CD25 fluctuates in the leukemia-initiating cell population of CD25-positive AML","volume":"13","author":"Kageyama","year":"2018","journal-title":"PLoS One"},{"key":"B69","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1111\/bjh.13941","article-title":"CD45RA, a specific marker for leukaemia stem cell sub-populations in acute myeloid leukaemia","volume":"173","author":"Kersten","year":"2016","journal-title":"Br. J. Haematol."},{"key":"B70","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.stem.2015.07.011","article-title":"A TIM-3\/Gal-9 autocrine stimulatory loop drives self-renewal of human myeloid leukemia stem cells and leukemic progression","volume":"17","author":"Kikushige","year":"2015","journal-title":"Cell Stem Cell"},{"key":"B71","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1038\/s41375-019-0684-5","article-title":"CD93 is expressed on chronic myeloid leukemia stem cells and identifies a quiescent population which persists after tyrosine kinase inhibitor therapy","volume":"34","author":"Kinstrie","year":"2020","journal-title":"Leukemia"},{"key":"B72","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/s0145-2126(96)00081-1","article-title":"Thy-1 expression on blast cells from adult patients with acute myeloid leukemia","volume":"21","author":"Kozii","year":"1997","journal-title":"Leuk. Res."},{"key":"B73","doi-asserted-by":"publisher","first-page":"447","DOI":"10.3324\/haematol.2017.169946","article-title":"CD36 defines primitive chronic myeloid leukemia cells less responsive to imatinib but vulnerable to antibody-based therapeutic targeting","volume":"103","author":"Landberg","year":"2018","journal-title":"Haematologica"},{"key":"B74","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1038\/367645a0","article-title":"A cell initiating human acute myeloid leukaemia after transplantation into SCID mice","volume":"367","author":"Lapidot","year":"1994","journal-title":"Nature"},{"key":"B75","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/cyto.b.20614","article-title":"Expression of the hMICL in acute myeloid leukemia-a highly reliable disease marker at diagnosis and during follow-up","volume":"82","author":"Larsen","year":"2012","journal-title":"Cytom. B Clin. Cytom."},{"key":"B76","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1182\/blood.2021014604","article-title":"An LSC-Based MRD assay to complement the traditional MFC method for prediction of AML relapse: a prospective study","volume":"140","author":"Li","year":"2022","journal-title":"Blood"},{"key":"B77","doi-asserted-by":"publisher","first-page":"2554","DOI":"10.1002\/1878-0261.13690","article-title":"Slow-replicating leukemia cells represent a leukemia stem cell population with high cell-surface CD74 expression","volume":"18","author":"Li","year":"","journal-title":"Mol. Oncol."},{"key":"B78","doi-asserted-by":"publisher","first-page":"5911","DOI":"10.1182\/blood-2024-203516","article-title":"A novel full-spectral flow cytometric assay for detection of measurable residual disease in patients with B-Lymphoblastic leukemia","volume":"144","author":"Li","year":"","journal-title":"Blood"},{"key":"B79","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1038\/s41409-025-02699-8","article-title":"Leukemia stem cells for relapse prediction in AML patients receiving allografts: long-term follow-up of a prospective study","volume":"60","author":"Li","year":"2025","journal-title":"Bone Marrow Transpl."},{"key":"B80","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s13287-021-02155-6","article-title":"CD9, a potential leukemia stem cell marker, regulates drug resistance and leukemia development in acute myeloid leukemia","volume":"12","author":"Liu","year":"2021","journal-title":"Stem Cell Res. Ther."},{"key":"B81","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1111\/bjh.17347","article-title":"Flow cytometric immunophenotypic alterations of persistent clonal haematopoiesis in remission bone marrows of patients with NPM1-mutated acute myeloid leukaemia","volume":"192","author":"Loghavi","year":"2021","journal-title":"Br. J. Haematol."},{"key":"B82","doi-asserted-by":"publisher","first-page":"106442","DOI":"10.1016\/j.leukres.2020.106442","article-title":"Plerixafor in combination with chemotherapy And\/or hematopoietic cell transplantation to treat acute leukemia: a systematic review and metanalysis of preclinical and clinical studies","volume":"97","author":"Maganti","year":"2020","journal-title":"Leuk. Res."},{"key":"B83","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1016\/j.stem.2007.10.001","article-title":"Identification of a hierarchy of multipotent hematopoietic progenitors in human cord blood","volume":"1","author":"Majeti","year":"2007","journal-title":"Cell Stem Cell"},{"key":"B84","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1182\/blood.v112.11.766.766","article-title":"CD47 is an independent prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells","volume":"112","author":"Majeti","year":"2008","journal-title":"Blood"},{"key":"B85","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/j.cell.2009.05.045","article-title":"CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells","volume":"138","author":"Majeti","year":"2009","journal-title":"Cell"},{"key":"B86","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1007\/s00428-024-03741-8","article-title":"Increased expression of CD70 in relapsed acute myeloid leukemia after hypomethylating agents","volume":"485","author":"Marques-Piubelli","year":"2024","journal-title":"Virchows Arch."},{"key":"B87","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1182\/blood.v128.22.1077.1077","article-title":"CD97 is a critical regulator of acute myeloid leukemia stem cell function","volume":"128","author":"Martin","year":"2016","journal-title":"Blood"},{"key":"B88","doi-asserted-by":"publisher","first-page":"2362","DOI":"10.1084\/jem.20190598","article-title":"CD97 is a critical regulator of acute myeloid leukemia stem cell function","volume":"216","author":"Martin","year":"2019","journal-title":"J. Exp. Med."},{"key":"B89","doi-asserted-by":"publisher","first-page":"3687","DOI":"10.3390\/cancers15143687","article-title":"Minimal residual disease in multiple myeloma: past, present, and future","volume":"15","author":"Medina-Herrera","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B90","doi-asserted-by":"publisher","first-page":"3182","DOI":"10.3324\/haematol.2023.283757","article-title":"CD74 is expressed in a subset of pediatric acute myeloid leukemia patients and is a promising target for therapy: a report from the children's oncology group","volume":"109","author":"Menssen","year":"2024","journal-title":"Haematologica"},{"key":"B91","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s40364-025-00769-z","article-title":"IL1RAP is an immunotherapeutic target for normal karyotype triple-mutated acute myeloid leukemia","volume":"13","author":"Metois","year":"2025","journal-title":"Biomark. Res."},{"key":"B92","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1634\/stemcells.2007-0861","article-title":"Identification of a small subpopulation of candidate leukemia-initiating cells in the side population of patients with acute myeloid leukemia","volume":"26","author":"Moshaver","year":"2008","journal-title":"Stem Cells"},{"key":"B93","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.leukres.2019.04.004","article-title":"Relationship between CD34\/CD38 and side population (SP) defined leukemia stem cell compartments in acute myeloid leukemia","volume":"81","author":"Moshaver","year":"2019","journal-title":"Leuk. Res."},{"key":"B94","unstructured":"Cancer stat facts: Acute myeloid leukemia (AML)\n          \n          \n          2024"},{"key":"B95","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1038\/nature20598","article-title":"A 17-gene stemness score for rapid determination of risk in acute leukaemia","volume":"540","author":"Ng","year":"2016","journal-title":"Nature"},{"key":"B96","doi-asserted-by":"publisher","first-page":"2657","DOI":"10.1182\/blood.2022019160","article-title":"Prospective validation of the prognostic relevance of CD34+CD38- AML stem cell frequency in the HOVON-SAKK132 trial","volume":"141","author":"Ngai","year":"2023","journal-title":"Blood"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2024.287090","article-title":"Different features of acute myeloid leukemia stem cell quantification in intensively treated patients","author":"Ngai","year":"2025","journal-title":"Haematologica"},{"key":"B99","doi-asserted-by":"publisher","first-page":"2890","DOI":"10.1182\/blood.v116.21.2890.2890","article-title":"Targeting of CLEC12A in acute myeloid leukemia by antibody-drug-conjugates and bispecific CLL-1\u00d7CD3 BiTE antibody","volume":"116","author":"Noordhuis","year":"2010","journal-title":"Blood"},{"key":"B100","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1126\/science.1201219","article-title":"Isolation of single human hematopoietic stem cells capable of long-term multilineage engraftment","volume":"333","author":"Notta","year":"2011","journal-title":"Science"},{"key":"B101","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1182\/blood-2019-129916","article-title":"Targeting CD70 with cusatuzumab eliminates acute myeloid leukemia stem cells in humans","volume":"134","author":"Ochsenbein","year":"2019","journal-title":"Blood"},{"key":"B102","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1111\/bph.16149","article-title":"Targeting integrins in drug-resistant acute myeloid leukaemia","volume":"181","author":"Ogana","year":"2024","journal-title":"Br. J. Pharmacol."},{"key":"B103","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1182\/blood-2015-11-683649","article-title":"GPR56 identifies primary human acute myeloid leukemia cells with high repopulating potential in vivo","volume":"127","author":"Pabst","year":"2016","journal-title":"Blood"},{"key":"B104","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.1158\/2159-8290.CD-22-1297","article-title":"A novel type of monocytic leukemia stem cell revealed by the clinical use of Venetoclax-Based therapy","volume":"13","author":"Pei","year":"2023","journal-title":"Cancer Discov."},{"key":"B105","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1002\/cyto.a.24284","article-title":"OMIP 072: a 15-color panel for immunophenotypic identification, quantification, and characterization of leukemic stem cells in children with acute myeloid leukemia","volume":"99","author":"Petersen","year":"2021","journal-title":"Cytom. A"},{"key":"B106","doi-asserted-by":"publisher","first-page":"8780","DOI":"10.1182\/blood-2022-168383","article-title":"CD69 marks leukemic regenerating cells and regulates their metabolism in AML","volume":"140","author":"Qiu","year":"2022","journal-title":"Blood"},{"key":"B107","first-page":"15","article-title":"Functional and genetic heterogeneity of distinct leukemic stem cell populations in CD34- human acute myeloid leukemia","volume-title":"Blood","author":"Quek","year":"2014"},{"key":"B108","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1084\/jem.20151775","article-title":"Genetically distinct leukemic stem cells in human CD34 acute myeloid leukemia are arrested at a hemopoietic precursor-like stage","volume":"213","author":"Quek","year":"2016","journal-title":"J. Exp. Med."},{"key":"B109","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1016\/j.exphem.2009.10.001","article-title":"Aldehyde dehydrogenase activity among primary leukemia cells is associated with stem cell features and correlates with adverse clinical outcomes","volume":"37","author":"Ran","year":"2009","journal-title":"Exp. Hematol."},{"key":"B110","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1016\/j.ccell.2016.10.014","article-title":"Sticking it to the niche: CD98 mediates critical adhesive signals in AML","volume":"30","author":"Reinisch","year":"2016","journal-title":"Cancer Cell"},{"key":"B111","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1002\/cyto.b.22201","article-title":"The role of the primitive marker CD133 in CD34-negative acute myeloid leukemia for the detection of leukemia stem cells","volume":"108","author":"Reuvekamp","year":"","journal-title":"Cytom. B Clin. Cytom."},{"key":"B112","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1038\/s41375-025-02539-0","article-title":"CD34+CD38-leukemia stem cells predict clinical outcomes in acute myeloid leukemia patients treated non-intensively with hypomethylating agents","volume":"39","author":"Reuvekamp","year":"","journal-title":"Leukemia"},{"key":"B113","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1158\/2643-3230.BCD-20-0208","article-title":"NOT-gated CD93 CAR T cells effectively target AML with minimized endothelial cross-reactivity","volume":"2","author":"Richards","year":"2021","journal-title":"Blood Cancer Discov."},{"key":"B114","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1084\/jem.20152008","article-title":"CD70\/CD27 signaling promotes blast stemness and is a viable therapeutic target in acute myeloid leukemia","volume":"214","author":"Riether","year":"2017","journal-title":"J. Exp. Med."},{"key":"B115","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.3324\/haematol.2017.183418","article-title":"Phase I trial of plerixafor combined with decitabine in newly diagnosed older patients with acute myeloid leukemia","volume":"103","author":"Roboz","year":"2018","journal-title":"Haematologica"},{"key":"B116","doi-asserted-by":"publisher","first-page":"375","DOI":"10.11406\/rinketsu.56.375","article-title":"Maintenance of leukemic and normal hematopoietic stem cells in bone marrow niches by EVI1-regulated GPR56","volume":"56","author":"Saito","year":"2015","journal-title":"Rinsho Ketsueki"},{"key":"B117","doi-asserted-by":"publisher","first-page":"17ra9","DOI":"10.1126\/scitranslmed.3000349","article-title":"Identification of therapeutic targets for quiescent, chemotherapy-resistant human leukemia stem cells","volume":"2","author":"Saito","year":"2010","journal-title":"Sci. Transl. Med."},{"key":"B118","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1182\/blood-2019-126271","article-title":"The first-in-class Anti-CD47 antibody magrolimab (5F9) in combination with azacitidine is effective in MDS and AML patients: ongoing phase 1b results","volume":"134","author":"Sallman","year":"2019","journal-title":"Blood"},{"key":"B119","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1172\/JCI41495","article-title":"Human acute myelogenous leukemia stem cells are rare and heterogeneous when assayed in NOD\/SCID\/IL2R\u03b3c-deficient mice","volume":"121","author":"Sarry","year":"2011","journal-title":"J. Clin. Invest"},{"key":"B120","doi-asserted-by":"publisher","first-page":"e78897","DOI":"10.1371\/journal.pone.0078897","article-title":"Normal hematopoietic stem cells within the AML bone marrow have a distinct and higher ALDH activity level than co-existing leukemic stem cells","volume":"8","author":"Schuurhuis","year":"2013","journal-title":"PLoS One"},{"key":"B121","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1182\/blood-2017-09-801498","article-title":"Minimal\/Measurable residual disease in AML: a consensus document from the european LeukemiaNet MRD working party","volume":"131","author":"Schuurhuis","year":"2018","journal-title":"Blood"},{"key":"B122","doi-asserted-by":"publisher","first-page":"3915","DOI":"10.1182\/blood.v128.22.3915.3915","article-title":"Single-cell gene expression analysis identifies alcam as a novel candidate therapeutic target in AML","volume":"128","author":"Shimura-Nukina","year":"2016","journal-title":"Blood"},{"key":"B123","doi-asserted-by":"publisher","first-page":"1890","DOI":"10.1001\/jamaoncol.2020.4600","article-title":"Association of measurable residual disease with survival outcomes in patients with acute myeloid leukemia: a systematic review and meta-analysis","volume":"6","author":"Short","year":"2020","journal-title":"JAMA Oncol."},{"key":"B124","doi-asserted-by":"publisher","first-page":"2866","DOI":"10.3390\/cancers15102866","article-title":"Acute myeloid leukemia stem cells in minimal\/measurable residual disease detection","volume":"15","author":"Srinivasan Rajsri","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B125","doi-asserted-by":"publisher","first-page":"1976","DOI":"10.1182\/blood-2009-02-206565","article-title":"Leukemia-initiating cells from some acute myeloid leukemia patients with mutated nucleophosmin reside in the CD34(-) fraction","volume":"115","author":"Taussig","year":"2010","journal-title":"Blood"},{"key":"B126","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1182\/blood.v77.6.1218.bloodjournal7761218","article-title":"Sequential generations of hematopoietic colonies derived from single nonlineage-committed CD34+CD38-progenitor cells","volume":"77","author":"Terstappen","year":"1991","journal-title":"Blood"},{"key":"B127","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1182\/blood.v116.21.759.759","article-title":"Accurate detection of residual leukemic stem cells in remission bone marrow predicts relapse in acute myeloid leukemia patients","volume":"116","author":"Terwijn","year":"2010","journal-title":"Blood"},{"key":"B128","doi-asserted-by":"publisher","first-page":"3889","DOI":"10.1200\/JCO.2012.45.9628","article-title":"High prognostic impact of flow cytometric minimal residual disease detection in acute myeloid leukemia: data from the HOVON\/SAKK AML 42A study","volume":"31","author":"Terwijn","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"B129","doi-asserted-by":"publisher","first-page":"e107587","DOI":"10.1371\/journal.pone.0107587","article-title":"Leukemic stem cell frequency: a strong biomarker for clinical outcome in acute myeloid leukemia","volume":"9","author":"Terwijn","year":"2014","journal-title":"PLoS One"},{"key":"B130","doi-asserted-by":"publisher","first-page":"1756","DOI":"10.1007\/s12015-022-10349-5","article-title":"Leukemic stem cell signatures in acute myeloid leukemia-targeting the guardians with novel approaches","volume":"18","author":"Thakral","year":"2022","journal-title":"Stem Cell Rev. Rep."},{"key":"B131","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1182\/blood-2016-07-726307","article-title":"Standardized flow cytometry for highly sensitive MRD measurements in B-cell acute lymphoblastic leukemia","volume":"129","author":"Theunissen","year":"2017","journal-title":"Blood"},{"key":"B132","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1002\/cam4.2007","article-title":"CD9 in acute myeloid leukemia: prognostic role and usefulness to target leukemic stem cells","volume":"8","author":"Touzet","year":"2019","journal-title":"Cancer Med."},{"key":"B133","doi-asserted-by":"publisher","first-page":"5969","DOI":"10.1182\/blood-2023-181251","article-title":"Improving anti-tumor efficacy of CAR T-Cell therapy for acute myeloid leukemia (AML): results from a multi-drug interaction screening approach","volume":"142","author":"Unglaub","year":"2023","journal-title":"Blood"},{"key":"B134","doi-asserted-by":"publisher","first-page":"5064","DOI":"10.3390\/cancers15205064","article-title":"Measurable residual disease (MRD) by flow cytometry in adult B-Acute lymphoblastic leukaemia (B-ALL) and acute myeloid leukaemia (AML): correlation with molecular MRD testing and clinical outcome at one year","volume":"15","author":"van der Linde","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B135","first-page":"983","article-title":"Assessment of the normal or leukemic nature of CD34+ cells in acute myeloid leukemia with low percentages of CD34 cells","volume":"88","author":"van der Pol","year":"2003","journal-title":"Haematologica"},{"key":"B136","doi-asserted-by":"publisher","first-page":"6520","DOI":"10.1158\/1078-0432.CCR-05-0468","article-title":"High stem cell frequency in acute myeloid leukemia at diagnosis predicts high minimal residual disease and poor survival","volume":"11","author":"van Rhenen","year":"2005","journal-title":"Clin. Cancer Res."},{"key":"B137","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1038\/sj.leu.2404754","article-title":"Aberrant marker expression patterns on the CD34+CD38-stem cell compartment in acute myeloid leukemia allows to distinguish the malignant from the normal stem cell compartment both at diagnosis and in remission","volume":"21","author":"van Rhenen","year":"","journal-title":"Leukemia"},{"key":"B138","doi-asserted-by":"publisher","first-page":"2659","DOI":"10.1182\/blood-2007-03-083048","article-title":"The novel AML stem cell associated antigen CLL-1 aids in discrimination between normal and leukemic stem cells","volume":"110","author":"van Rhenen","year":"","journal-title":"Blood"},{"key":"B139","doi-asserted-by":"publisher","first-page":"4881","DOI":"10.3390\/ijms25094881","article-title":"The evolving landscape of flowcytometric minimal residual disease monitoring in B-Cell precursor acute lymphoblastic leukemia","volume":"25","author":"Verbeek","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"B140","doi-asserted-by":"publisher","first-page":"1792","DOI":"10.3324\/haematol.2011.047894","article-title":"High levels of CD34+CD38low\/-CD123+ blasts are predictive of an adverse outcome in acute myeloid leukemia: a Groupe Ouest-Est des Leucemies Aigues et Maladies du Sang (GOELAMS) study","volume":"96","author":"Vergez","year":"2011","journal-title":"Haematologica"},{"key":"B141","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1182\/bloodadvances.2018030726","article-title":"A parsimonious 3-gene signature predicts clinical outcomes in an acute myeloid leukemia multicohort study","volume":"3","author":"Wagner","year":"2019","journal-title":"Blood Adv."},{"key":"B142","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1038\/s41375-021-01230-4","article-title":"Measurable residual disease as a biomarker in acute myeloid leukemia: theoretical and practical considerations","volume":"35","author":"Walter","year":"2021","journal-title":"Leukemia"},{"key":"B143","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1097\/CM9.0000000000003362","article-title":"Chimeric antigen receptor T cells targeting CD312 as a therapy for acute myeloid leukemia","volume":"138","author":"Xie","year":"2025","journal-title":"Chin. Med. J. Engl."},{"key":"B144","doi-asserted-by":"publisher","first-page":"2144","DOI":"10.1080\/10428194.2017.1410888","article-title":"Expression of multiple leukemic stem cell markers is associated with poor prognosis in de novo acute myeloid leukemia","volume":"59","author":"Yabushita","year":"2018","journal-title":"Leuk. Lymphoma"},{"key":"B145","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1111\/bjh.13572","article-title":"Absence of leukaemic CD34(+) cells in acute myeloid leukaemia is of high prognostic value: a longstanding controversy deciphered","volume":"171","author":"Zeijlemaker","year":"2015","journal-title":"Br. J. Haematol."},{"key":"B146","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1038\/leu.2015.252","article-title":"A simple one-tube assay for immunophenotypical quantification of leukemic stem cells in acute myeloid leukemia","volume":"30","author":"Zeijlemaker","year":"2016","journal-title":"Leukemia"},{"key":"B147","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1038\/s41375-018-0326-3","article-title":"CD34(+)CD38(-) leukemic stem cell frequency to predict outcome in acute myeloid leukemia","volume":"33","author":"Zeijlemaker","year":"","journal-title":"Leukemia"},{"key":"B148","doi-asserted-by":"publisher","first-page":"e66","DOI":"10.1002\/cpcy.66","article-title":"Immunophenotypic detection of measurable residual (stem cell) disease using LAIP approach in acute myeloid leukemia","volume":"91","author":"Zeijlemaker","year":"","journal-title":"Curr. Protoc. Cytom."},{"key":"B149","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1158\/2643-3230.BCD-19-0077","article-title":"Apolipoprotein C2 - CD36 promotes leukemia growth and presents a targetable axis in acute myeloid leukemia","volume":"1","author":"Zhang","year":"2020","journal-title":"Blood Cancer Discov."},{"key":"B150","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1186\/s13059-023-03031-7","article-title":"Single-cell transcriptomics reveals multiple chemoresistant properties in leukemic stem and progenitor cells in pediatric AML","volume":"24","author":"Zhang","year":"2023","journal-title":"Genome Biol."},{"key":"B151","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s13045-024-01586-x","article-title":"IL1RAP-specific T cell engager depletes acute myeloid leukemia stem cells","volume":"17","author":"Zhang","year":"2024","journal-title":"J. Hematol. Oncol."},{"key":"B152","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1002\/cyto.a.24958","article-title":"Development of a 29\u2010Color single\u2010tube full spectrum flow cytometry assay for the detection of measurable residual disease and leukemic stem cells in acute myeloid leukemia","volume":"107","author":"Zhang","year":"2025","journal-title":"Cytom. Part A"},{"key":"B153","doi-asserted-by":"publisher","first-page":"865","DOI":"10.21037\/tcr-24-1550","article-title":"CD69 predicts prognosis through immune cell infiltration and decitabine treatment response in acute myeloid leukemia","volume":"14","author":"Zhou","year":"2025","journal-title":"Transl. Cancer Res."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1724473\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T06:35:33Z","timestamp":1765348533000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1724473\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,10]]},"references-count":150,"alternative-id":["10.3389\/fphar.2025.1724473"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2025.1724473","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,10]]},"article-number":"1724473"}}